ArticleBJU international2024

The immune-related adverse events paradox in locally advanced or metastatic urothelial cancer after atezolizumab immunotherapy: analysis of individual patient data from IMvigor210 and IMvigor211 trials.

Daniele Robesti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.